Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 102 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,000 | +42.9% | 5,467 | +74.4% | 0.00% | – |
| Q2 2023 | $21,000 | +110.0% | 3,135 | +50.8% | 0.00% | – |
| Q1 2023 | $10,000 | -76.2% | 2,079 | -76.0% | 0.00% | – |
| Q4 2022 | $42,000 | -50.0% | 8,660 | +48.9% | 0.00% | – |
| Q3 2022 | $84,000 | +1.2% | 5,816 | +5.4% | 0.00% | – |
| Q2 2022 | $83,000 | -26.5% | 5,519 | -41.7% | 0.00% | – |
| Q1 2022 | $113,000 | -45.1% | 9,471 | -25.6% | 0.00% | – |
| Q4 2021 | $206,000 | -53.6% | 12,723 | -18.2% | 0.00% | – |
| Q3 2021 | $444,000 | -11.7% | 15,560 | +4.6% | 0.00% | – |
| Q2 2021 | $503,000 | +78.4% | 14,870 | +59.8% | 0.00% | – |
| Q1 2021 | $282,000 | -35.5% | 9,306 | +5.4% | 0.00% | – |
| Q4 2020 | $437,000 | +52.8% | 8,833 | +18.7% | 0.00% | – |
| Q3 2020 | $286,000 | +18.2% | 7,439 | +32.3% | 0.00% | – |
| Q2 2020 | $242,000 | +7966.7% | 5,621 | +4745.7% | 0.00% | – |
| Q1 2020 | $3,000 | -84.2% | 116 | -81.3% | 0.00% | – |
| Q4 2019 | $19,000 | – | 619 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |